Impact of prior and concurrent medication on exacerbation risk with long-acting bronchodilators in chronic obstructive pulmonary disease: a post hoc analysis

被引：0
|
作者：
Ian Naya
Lee Tombs
David A. Lipson
Isabelle Boucot
Chris Compton
机构：
[1] Global Respiratory Franchise,Perelman School of Medicine
[2] GSK,undefined
[3] Precise Approach Ltd,undefined
[4] contingent worker on assignment at GSK,undefined
[5] Respiratory Research and Development,undefined
[6] GSK,undefined
[7] University of Pennsylvania,undefined
来源：
Respiratory Research | / 20卷
关键词：
COPD; Maintenance therapy; Exacerbation risk; ICS; Long acting bronchodilators; Lung function;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] Time-Dependent Risk of Cardiovascular Events Following an Exacerbation in Patients With Chronic Obstructive Pulmonary Disease: Post Hoc Analysis From the IMPACT Trial
    Dransfield, Mark T.
    Criner, Gerard J.
    Halpin, David M. G.
    Han, MeiLan K.
    Hartley, Benjamin
    Kalhan, Ravi
    Lange, Peter
    Lipson, David A.
    Martinez, Fernando J.
    Midwinter, Dawn
    Singh, Dave
    Wise, Robert
    Kunisaki, Ken M.
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2022, 11 (18):
  • [32] Long-acting muscarinic antagonist and long-acting beta 2-agonist therapy to optimize chronic obstructive pulmonary disease prior to lung cancer surgery
    Makino, Takashi
    Otsuka, Hajime
    Hata, Yoshinobu
    Koezuka, Satoshi
    Azuma, Yoko
    Isobe, Kazutoshi
    Sugino, Keishi
    Ebihara, Sitorlt
    Homma, Sakae
    Iyoda, Akira
    MOLECULAR AND CLINICAL ONCOLOGY, 2018, 8 (05) : 647 - 652
  • [33] Role of Long-Acting Muscarinic Antagonist/Long-Acting β2-Agonist Therapy in Chronic Obstructive Pulmonary Disease
    Petite, Sarah E.
    ANNALS OF PHARMACOTHERAPY, 2017, 51 (08) : 696 - 705
  • [34] Long-acting beta2-agonists for chronic obstructive pulmonary disease
    Kew, Kayleigh M.
    Mavergames, Chris
    Walters, Julia A. E.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2013, (10):
  • [35] Risk of pneumonia with inhaled corticosteroid/long-acting β2 agonist therapy in chronic obstructive pulmonary disease: a cluster analysis
    DiSantostefano, Rachael L.
    Li, Hao
    Hinds, David
    Galkin, Dmitry V.
    Rubin, David B.
    INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2014, 9 : 457 - 468
  • [36] Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network meta-analysis
    Oba, Yuji
    Keeney, Edna
    Ghatehorde, Namratta
    Dias, Sofia
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2018, (12):
  • [37] Long-Acting β2 Agonists in the Management of Stable Chronic Obstructive Pulmonary Disease
    Mario Cazzola
    Claudio Ferdinando Donner
    Drugs, 2000, 60 : 307 - 320
  • [38] Long-acting β2 agonists in the management of stable chronic obstructive pulmonary disease
    Cazzola, M
    Donner, CF
    DRUGS, 2000, 60 (02) : 307 - 320
  • [39] Tiotropium: An inhaled, long-acting anticholinergic drug for chronic obstructive pulmonary disease
    Panning, CA
    DeBisschop, M
    PHARMACOTHERAPY, 2003, 23 (02): : 183 - 189
  • [40] Efficiency and safety of roflumilast combined with long-acting bronchodilators on moderate-to-severe stable chronic obstructive pulmonary disease patients: a meta-analysis
    Luo, Peng
    Li, Shuo
    Chen, Yitai
    Luo, Yuwen
    Li, Yun
    Wang, Kai
    Huang, Yuxia
    Chen, Xin
    JOURNAL OF THORACIC DISEASE, 2016, 8 (09) : 2638 - +
12345